GSK plc clinched a partnership with Chinese vaccine maker Chongqing Zhifei Biological Products Co to boost sales of its blockbuster shingles immunisation locally.   Under the agreement, GSK will sell £2.5 billion worth of its Shingrix shot to Zhifei over a three-year period. The Chinese company, which already distributes Merck & Co's Gardasil, will promote the shot across 30,000 vaccination points to spur its uptake, GSK said in a statement on Monday. Tapping growing demand among China's swelling ranks of senior citizens could help GSK reach its goal of doubling Shingrix's revenue to more than £4 billion by 2026 - especially as demand cools in other markets.

http://klse.i3investor.com/web/blog/detail/kianweiaritcles/2023-10-09-story-h-218002507-GSK_partners_with_Chinese_vaccine_maker_to_boost_shingles_shot_sales

#i3investor